D6

Genedrive PLCFRA Genedrive Stock Report

Last reporting period 31 Dec, 2023

Updated 29 Oct, 2024

Last price

Market cap $B

0.012

Micro

Exchange

XFRA - Deutsche Boerse AG

D6M.F Stock Analysis

D6

Avoid

Based on Eyestock quantitative analysis, D6M.F`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-53/100

Low score

Market cap $B

0.012

Dividend yield

Shares outstanding

92.535 B

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The firm offers products, including Genedrive MT-RNR1 ID Kit and Genedrive COV19-ID Kit. The firm has two point-of-care tests on the market, which include Covid-19 and to help in the prevention of hearing loss caused by certain antibiotics in neonates. In addition, the Company also has assays on market for the detection of hepatitis c virus (HCV), certain military biological targets and a high throughput SARS-CoV-2 assay.

View Section: Eyestock Rating